G P Fadini1, M Albiero2, S Vigili de Kreutzenberg2, A Avogaro2. 1. Department of Medicine, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy. gianpaolofadini@hotmail.com. 2. Department of Medicine, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
Abstract
PURPOSE: Hypoglycemia is a barrier to the achievement of glycemic targets and limits the beneficial effects of improved glucose control on cardiovascular outcomes in type 2 diabetes (T2D). Circulating endothelial progenitor cells (EPCs) participate in cardiovascular homeostasis and predict future cardiovascular events. Therefore, we herein analyzed the association between occurrence of hypoglycemia and EPC changes in T2D patients after optimization of glucose control with basal insulin therapy. METHODS: In the NCT00699686 trial, 42 T2D insulin-naïve patients received a3 + 3-month cross-over therapy with glargine and detemir. There were 43 minor and 2 severe hypoglycemic episodes in 19 patients (45.2 %, 0.54 episodes/patient/year). Changes in EPCs were analyzed in relation to the occurrence of hypoglycemia during the trial. RESULTS: Patients with hypoglycemia had a higher final HbA1c at 6 months than patients without, although absolute HbA1c changes were not significantly different. Though PCs increased at study end, in patients experiencing at least 1 hypoglycemic episode, the changes in CD34(+), CD133(+) progenitor cells and CD34(+)KDR(+) EPCs were significantly lower than the respective changes in patients without incident hypoglycemia, even after correcting for confounders. During treatment with detemir, which induced >twofold less hypoglycemia than glargine, CD34(+)KDR(+) EPCs increased significantly more than during treatment with glargine. CONCLUSIONS: In naïve T2D patients initiating basal insulin, hypoglycemia prevents the increase in vasculoprotective PCs. Clinically, these data strengthen the importance of avoiding hypoglycemia to improve cardiovascular outcomes during the treatment of T2D.
RCT Entities:
PURPOSE:Hypoglycemia is a barrier to the achievement of glycemic targets and limits the beneficial effects of improved glucose control on cardiovascular outcomes in type 2 diabetes (T2D). Circulating endothelial progenitor cells (EPCs) participate in cardiovascular homeostasis and predict future cardiovascular events. Therefore, we herein analyzed the association between occurrence of hypoglycemia and EPC changes in T2D patients after optimization of glucose control with basal insulin therapy. METHODS: In the NCT00699686 trial, 42 T2D insulin-naïve patients received a 3 + 3-month cross-over therapy with glargine and detemir. There were 43 minor and 2 severe hypoglycemic episodes in 19 patients (45.2 %, 0.54 episodes/patient/year). Changes in EPCs were analyzed in relation to the occurrence of hypoglycemia during the trial. RESULTS:Patients with hypoglycemia had a higher final HbA1c at 6 months than patients without, although absolute HbA1c changes were not significantly different. Though PCs increased at study end, in patients experiencing at least 1 hypoglycemic episode, the changes in CD34(+), CD133(+) progenitor cells and CD34(+)KDR(+) EPCs were significantly lower than the respective changes in patients without incident hypoglycemia, even after correcting for confounders. During treatment with detemir, which induced >twofold less hypoglycemia than glargine, CD34(+)KDR(+) EPCs increased significantly more than during treatment with glargine. CONCLUSIONS: In naïve T2D patients initiating basal insulin, hypoglycemia prevents the increase in vasculoprotective PCs. Clinically, these data strengthen the importance of avoiding hypoglycemia to improve cardiovascular outcomes during the treatment of T2D.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette Journal: Cell Date: 2006-01-27 Impact factor: 41.582
Authors: Rohana J Wright; David E Newby; David Stirling; Christopher A Ludlam; Ian A Macdonald; Brian M Frier Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: Gian Paolo Fadini; Shoichi Maruyama; Takenori Ozaki; Akihiko Taguchi; James Meigs; Stefanie Dimmeler; Andreas M Zeiher; Saula de Kreutzenberg; Angelo Avogaro; Georg Nickenig; Caroline Schmidt-Lucke; Nikos Werner Journal: PLoS One Date: 2010-07-09 Impact factor: 3.240
Authors: Stephen S Johnston; Christopher Conner; Mark Aagren; David M Smith; Jonathan Bouchard; Jason Brett Journal: Diabetes Care Date: 2011-03-18 Impact factor: 19.112
Authors: F Boscari; M D'Anna; B M Bonora; S Tresso; R Cappellari; A Avogaro; D Bruttomesso; G P Fadini Journal: J Endocrinol Invest Date: 2020-05-04 Impact factor: 4.256
Authors: W Riski Widya Mulyani; Made Indira Dianti Sanjiwani; I Putu Yuda Prabawa; Anak Agung Wiradewi Lestari; Desak Made Wihandani; Ketut Suastika; Made Ratna Saraswati; Agha Bhargah; Ida Bagus Amertha Putra Manuaba Journal: Diabetes Metab Syndr Obes Date: 2020-02-27 Impact factor: 3.168
Authors: Caroline Jane Magri; Dillon Mintoff; Liberato Camilleri; Robert G Xuereb; Joseph Galea; Stephen Fava Journal: J Diabetes Res Date: 2018-07-22 Impact factor: 4.011